Evan Picard
Evan’s leadership journey has seen him play pivotal roles in shaping business strategies across multiple industries. Before joining MMS, Evan was Vice President of Finance at Parexel, having previously made significant contributions to renowned entities such as Syneos Health, PRA Health Sciences, and RTI International. His ability to forge strong teams and provide forward-looking insights positions him as a cornerstone of MMS’s future growth.
As Chief Financial Officer of MMS, Evan serves as the global head of the Accounting, Finance, Human Resources, and Talent Acquisition functions. Evan and his team are responsible for: financial planning and analysis, consolidations under US GAAP, treasury, HR leadership, and recruiting services. Evan’s role underscores MMS Holdings’ commitment to top-tier financial stewardship, talent development, and MMS’ growth-oriented mindset. His unique blend of experience and acumen promises to steer the company toward continued financial success.
What we have here at MMS is very special. We have great staff who deliver day in and day out for our clients and our organization. The expertise we bring to the market is top tier, and it shows through our customer satisfaction scores and our customer retention rates. In my organization, we aim to provide high quality services and solutioning for our internal and external partners. My team accomplishes this by exemplifying our corporate values, like “Wow the Customer” and “SOUL” (Sense Of Urgency Leadership). I’m very proud of the work we do at MMS and I’m excited to continue on our journey of evolution and growth as a company delivering value to our clients and bringing new therapies to patients swiftly and creatively.
Evan has a BS – Management degree from Virginia Tech (Pamplin College of Business) and an MBA from the College of William & Mary (Mason School of Business).
Suggested For You
perspectives
February 13th, 2025
Helping European Drug Development Companies Succeed in the US Market
news
February 12th, 2025
MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO
perspectives
January 30th, 2025
Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned
perspectives
January 21st, 2025
REMS Modifications and Revisions: A Retrospective from the Past 12 Months
regulatory intelligence
January 17th, 2025
The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development
regulatory intelligence
January 17th, 2025
New FDA Protocol Deviation Guidance: Planning for the Things That Don’t Go According to Plan
perspectives
January 9th, 2025
How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA
perspectives
January 2nd, 2025
Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations
perspectives
December 17th, 2024
Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs
perspectives
December 11th, 2024
Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs
regulatory intelligence
December 4th, 2024
FDA Issues Detailed Guidance on Development of Gene Therapy Products
news
December 4th, 2024
AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium